Healthcare Industry News: reprocessing
News Release - December 19, 2006
Cantel Medical Corp. Announces New President and CEOLITTLE FALLS, N.J.--(HSMN NewsFeed)--CANTEL MEDICAL CORP. (NYSE:CMN ) today announced the appointment of R. Scott Jones as President and Chief Executive Officer of the Company. Mr. Jones, who was selected following an extensive national search, is a veteran of the healthcare products and services industry. He most recently served as President and CEO of Symphony Health Services, Inc., a leading provider of contract healthcare services with over 6,000 employees. Symphony Health Services was acquired by RehabCare Group Inc. (NYSE: RHB ) in July 2006.
Prior to joining Symphony, Mr. Jones served as President and CEO of Accentia, Inc., an international specialty bio-pharmaceutical company, and as Chief Operating Officer at PharMerica, Inc., a provider of pharmacy products and services for specialized patient populations in long-term care and alternate care facilities, which was acquired by AmerisourceBergen Corporation (formerly Bergen Brunswick Corp.).
Mr. Jones' background also includes extensive experience with global medical product companies, including an eight-year tenure with General Electric Medical Systems, where he led the X-Ray Products group for North and South America and held an international assignment in Tokyo, Japan. He currently serves as a Director for American Radiology Services, an affiliate of the Johns Hopkins University School of Medicine. Mr. Jones holds a Masters Degree in bioengineering from Pennsylvania State University and a Bachelors degree in biochemistry and biophysics from the State University of New York.
"The Cantel Board conducted a comprehensive search for the strongest candidate to lead the next stage of our growth," said Charles Diker, Chairman of the Board. "We are thrilled to bring Scott on board and believe his healthcare and acquisition experience will be a tremendous asset to the Company. With the successful integration of our Crosstex acquisition, the continuing development of Mar Cor Purification, and Minntech's leadership position in dialysis and endoscope reprocessing, Scott is arriving at a critical stage of our development. We are confident in Scott's ability to grow our core infection prevention and control businesses and to help us expand through acquisitions and other growth opportunities."
Mr. Jones stated, "I'm very pleased to join the Cantel team. The Company is well poised in the infection prevention and control marketplace for profitable growth via new product introductions, acquisitions and an expanded international presence. Given the importance of infection control in providing quality, cost-effective healthcare, Cantel's range of solutions and technologies addresses an area with growing focus and demand."
Mr. Jones succeeds James P. Reilly, who is retiring after serving as President and CEO since 1989. "Jim has led Cantel for over 17 years, during which time we have grown and developed from a company with modest revenues and no proprietary products, to a leading manufacturer and provider of infection prevention and control products with over $200 million in sales," said Mr. Diker. "Jim has made major contributions to our growth and success and I want to thank him on behalf of our Board, stockholders and employees for his dedicated years of service."
Cantel Medical Corp. is a leading provider of infection prevention and control products in the healthcare market. Our products include specialized medical device reprocessing systems for renal dialysis and endoscopy, dialysate concentrates and other dialysis supplies, disposable infection control products primarily for the dental industry, water purification equipment, sterilants, disinfectants and cleaners, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens.
This press release contains forward-looking statements. All forward-looking statements involve risks and uncertainties, including, without limitation, the risks detailed in the Company's filings and reports with the Securities and Exchange Commission. Such statements are only predictions, and actual events or results may differ materially from those projected.
For further information, visit the Cantel website at www.cantelmedical.com.
Source: Cantel Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.